Assembly Biosciences (ASMB) Earnings Date & Reports

Key Takeaways

• Assembly Biosciences is expected to report its third-quarter 2026 results after the market close on Monday, November 9, 2026, according to consensus tracking sources.
• Analyst estimates point to a net loss of roughly $0.62 to $0.66 per share, with quarterly revenue expected near $9.1 million.
• In the prior quarter (Q2 2026), the company posted a narrower-than-expected loss of $0.20 per share on revenue of $13.37 million, topping consensus on both metrics.
• The company held approximately $226.6 million in cash and marketable securities as of March 31, 2026, which management says funds operations into 2028.
• Investors will focus on pipeline updates, including the Phase 2 initiation timeline for its hepatitis delta candidate and the search for a partner for its hepatitis B program.
• For more information about the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages linked here.
• Readers can also explore Trending AI Robots for AI-driven trading strategies and market insights.

Earnings Context and Why It Matters

Assembly Biosciences is a clinical-stage biotechnology company developing therapies for serious viral diseases, including recurrent genital herpes, hepatitis B (HBV), hepatitis delta (HDV), and transplant-related herpesviruses. With no approved products yet, its quarterly results revolve around collaboration revenue, research and development (R&D) spending, and pipeline execution rather than product sales. The upcoming report matters because it will offer fresh visibility into a landmark December 2025 licensing deal with Gilead Sciences, which secured exclusive rights to the company's helicase-primase inhibitor program for recurrent genital herpes in exchange for a $35.0 million payment. Investors will also be watching for signs of clinical progress across a maturing pipeline that could reshape the company's long-term value.

Earnings Expectations

Consensus estimates compiled by financial data providers call for Assembly Biosciences to report a net loss in the range of roughly $0.62 to $0.66 per share for the third quarter of 2026, with revenue expected near $9.1 million. For context, the company reported a loss of $0.72 per share on revenue of $10.79 million in the same quarter a year earlier, implying a modest expected year-over-year revenue decline as collaboration activities shift.

Expectations remain fluid because the company's revenue is tied to milestone-driven collaboration work rather than recurring product sales. In its most recent quarter, Assembly Biosciences delivered a narrower-than-expected loss of $0.20 per share and revenue of $13.37 million, beating consensus estimates on both lines, and has topped EPS expectations in seven of its last eight quarters. Beyond the headline figures, analysts will watch operating expense trends, cash burn, and any updates on partnership economics tied to the Gilead collaboration.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical companion for monitoring names like ASMB around earnings events. Explore the AI Screener to streamline your research process.

Market Reaction and Investor Sentiment

Sentiment heading into the report has been cautious, with ASMB shares trading well below their 50-day and 200-day moving averages and down more than 30% over the trailing 52-week period. The stock has historically shown meaningful single-day moves around earnings, gaining more than 10% the day after its August 2026 release while slipping after its May 2026 report. Because Assembly Biosciences is a clinical-stage company with limited recurring revenue, price swings are often driven by pipeline commentary and partnership news rather than top- or bottom-line results alone. Key risk factors include the timing and costs of clinical trials, potential dilution from capital raises, and the company's dependence on its Gilead collaboration for near-term funding and development of its lead programs.

Forward Outlook and Key Factors to Monitor

Looking beyond the quarterly numbers, investors will focus on several pipeline catalysts. The company has said it expects to initiate a Phase 2 study for its HDV candidate, known as ABI-6250, in the fourth quarter of 2026, so any confirmation or refinement of that timeline will be closely watched. Progress under the Gilead collaboration is another central theme, including the timing of potential Phase 2 studies for the helicase-primase inhibitor program and the company's decision on a U.S. profit-share option.

Separately, the hepatitis B program (ABI-4334) remains a key variable. After Gilead declined to exercise its option on that asset in March 2026, Assembly Biosciences retained full control and is actively seeking a partner; the company has indicated it does not plan to advance the program without one. Any update on partnership discussions could meaningfully influence sentiment.

Finally, investors should monitor cash runway and operating expense discipline. With more than $226 million in cash and marketable securities as of the end of the first quarter, management has said the balance sheet supports operations into 2028. Continued capital efficiency, along with progress on the regulatory filing-enabling studies for its next-generation candidates, will remain important factors shaping the company's trajectory through the rest of 2026 and beyond.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations